___

1. Lavie KS, MiCallef JM, Pimenta JM, Forssen UM. Prevalence of thrombocytopenia among patients with chronic hepatitis C: Asystematic review. J Viral Hepat. 2011;18(1):1-7.

2. Giannini EG, Afdhal NH, Sigal SH, Muir AJ, Reddy KR, Vijayaraghavan S, Elkashab M, Romero-Gómez M, Dusheiko GM, Iyengar M, Vasey SY, Campbell FM, Theodore D. Non cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.J Gastroenterol Hepatol. 2015;30(8):1301-8.

3. Fouad YM1.Chronic hepatitis C-associated thrombocytopenia: aetiology and management. Trop Gastroenterol. 2013;34(2):58-67.

4. Rajan S, Liebman HA. Treatment of hepatitis C related thrombocytopenia with interferon alpha. Am J Hematol. 2001;68(3):202-9.

5. Giannini E, Borro P, Botta F, Fumagalli A, Malfatti F, Podesta E, Romagnoli P, Testa E. Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. J Hepatol. 2002;37(5):572-7.

6. Alvarez GC, Gomez-Galicia D Rodrigu-Fragos, Marina VM, Dorantes LC, SanchezAleman M., Mendez- Sanchez N, Esparza JR. Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin. Ann of Hepatol. 2011;10(4):458-68.

7. Schreiber AD, Chien P, Tomaski A, Cines DB. Effect of danazol in immune thrombocytopenic purpura. N Engl J Med. 1987;316(9):503-8.

8. Mylvaganam R, Ahn YS, Harrington WJ, Kim CI. Immune modulation by danazol in autoimmune thrombocytopenia. Clin Immunol Immunopathol. 1987;42(3):281-7.

9. West SG, Johnson SC. Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med. 1988;108(5):703-6.

10. Ahn YS, Harrington WJ, Simon SR, Mylvaganam R, Pall LM, So AG. Danazol for the treatment of idiopathic thrombocytopenic purpura. N Engl J Med. 1983;308(23):1396- 9.

11. Ahn YS, Horstman LL. Idiopathic thrombocytopenic purpura: Pathology and management. Int J Hematol. 2002;76(Suppl 2):123-31.

12. Maloisel F, Andres E, Zimmer J, Noel E, Zamfir A, Koumarianou A, Dufour P. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: Long term results. Am J Med. 2004;116(9):590-4.

13. McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, Blackman N, Jenkins J, Afdhal NH; TPL102357 Study Group. Eltrombopage for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357(22):2227-36.

14. Romano F , Ruggeri M, Coretti S, Giannini EG, Sacchini D, Annichiarico BE, Marchetti M, Rodeghiero F, Lidonnici D. Economic assessment of eltrombopag in the treatment of thrombocytopenia. Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):713-20.

15. Afdhal NH, Dusheiko GM, Giannini EG, Chen PJ, Han KH, Mohsin A, RodriguezTorres M, Rugina S, Bakulin I, Lawitz E, Shiffman ML, Tayyab GU, Poordad F, Kamel YM, Brainsky A, Geib J, Vasey SY, Patwardhan R, Campbell FM, Theodore D. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. Gastroenterology. 2014;146(2):442-52.

16. Mihăilă RG1, Cipăian RC. Eltrombopag in chronic hepatitis C. World J Gastroenterol. 2014;20(35):12517-21.

17. Saleh MI, Obeidat AR, Anter HA, Khanfar AA. Eltrombopag dose predictors in thrombocytopenic subjects with hepatitis C virus infection. Clin Exp Pharmacol Physiol. 2015;42(10):1030-5.